BACKGROUND: Conflicting data exist regarding the effect of pregnancy on steady-state nevirapine pharmacokinetics (PK), although steady-state nevirapine concentrations during pregnancy have never been characterized in sub-Saharan Africa. METHODS: This was a longitudinal intensive PK study in Ugandan pregnant women receiving nevirapine-based antiretroviral therapy. Participants underwent intensive 12-hour PK sampling during the second trimester (T2; n = 4), third trimester (T3; n = 15) and 6 weeks postpartum (PP; n = 15). HIV-1 RNA was performed within 2 weeks of each visit. Nevirapine C12 above 3000 ng/mL was classified as optimal based on the suggested value for therapeutic drug monitoring. RESULTS: The pharmacokinetics of nevirapine were influenced by pregnancy, demonstrated by a 20% reduction in the maximum concentration, minimum concentration (C12), and area under the curve between T3 and PP visits (P = 0.001, P = 0.011 and P = 0.005, respectively). Ten subjects (66.7%) had C12 values <3000 ng/mL during T3. Of these participants, 7 partcipant's C12 concentrations increased to >3000 ng/mL during the PP visit. HIV-1 RNA were <1000 copies per milliliter at T3 and <400 copies per milliliter at PP in all patients. CONCLUSIONS: Nevirapine exposure was reduced in Ugandan women during their third trimester compared with the same women PP, however, HIV RNA remained <1000 copies per milliliter. The long-term impact of intermittent suboptimal nevirapine concentrations during pregnancy is unknown.
BACKGROUND: Conflicting data exist regarding the effect of pregnancy on steady-state nevirapine pharmacokinetics (PK), although steady-state nevirapine concentrations during pregnancy have never been characterized in sub-Saharan Africa. METHODS: This was a longitudinal intensive PK study in Ugandan pregnant women receiving nevirapine-based antiretroviral therapy. Participants underwent intensive 12-hour PK sampling during the second trimester (T2; n = 4), third trimester (T3; n = 15) and 6 weeks postpartum (PP; n = 15). HIV-1 RNA was performed within 2 weeks of each visit. Nevirapine C12 above 3000 ng/mL was classified as optimal based on the suggested value for therapeutic drug monitoring. RESULTS: The pharmacokinetics of nevirapine were influenced by pregnancy, demonstrated by a 20% reduction in the maximum concentration, minimum concentration (C12), and area under the curve between T3 and PP visits (P = 0.001, P = 0.011 and P = 0.005, respectively). Ten subjects (66.7%) had C12 values <3000 ng/mL during T3. Of these participants, 7 partcipant's C12 concentrations increased to >3000 ng/mL during the PP visit. HIV-1 RNA were <1000 copies per milliliter at T3 and <400 copies per milliliter at PP in all patients. CONCLUSIONS:Nevirapine exposure was reduced in Ugandan women during their third trimester compared with the same women PP, however, HIV RNA remained <1000 copies per milliliter. The long-term impact of intermittent suboptimal nevirapine concentrations during pregnancy is unknown.
Authors: M C Marazzi; P Germano; G Liotta; G Guidotti; S Loureiro; A da Cruz Gomes; M C Valls Blazquez; P Narciso; C F Perno; S Mancinelli; L Palombi Journal: HIV Med Date: 2006-07 Impact factor: 3.180
Authors: Alice M Stek; Mark Mirochnick; Edmund Capparelli; Brookie M Best; Chengcheng Hu; Sandra K Burchett; Carol Elgie; Diane T Holland; Elizabeth Smith; Ruth Tuomala; Amanda Cotter; Jennifer S Read Journal: AIDS Date: 2006-10-03 Impact factor: 4.177
Authors: S R Penzak; G Kabuye; P Mugyenyi; F Mbamanya; V Natarajan; R M Alfaro; C Kityo; E Formentini; H Masur Journal: HIV Med Date: 2007-03 Impact factor: 3.180
Authors: Jashvant D Unadkat; Diane W Wara; Michael D Hughes; Anita A Mathias; Diane T Holland; Mary E Paul; James Connor; Sharon Huang; Bach-Yen Nguyen; D Heather Watts; Lynne M Mofenson; Elizabeth Smith; Paul Deutsch; Kathleen A Kaiser; Ruth E Tuomala Journal: Antimicrob Agents Chemother Date: 2006-12-11 Impact factor: 5.191
Authors: Christoph Wyen; Heidy Hendra; Martin Vogel; Christian Hoffmann; Heribert Knechten; Norbert H Brockmeyer; Johannes R Bogner; Jürgen Rockstroh; Stefan Esser; Hans Jaeger; Thomas Harrer; Stefan Mauss; Jan van Lunzen; Nicole Skoetz; Alexander Jetter; Christiane Groneuer; Gerd Fätkenheuer; Saye H Khoo; Deirdre Egan; David J Back; Andrew Owen Journal: J Antimicrob Chemother Date: 2008-02-14 Impact factor: 5.790
Authors: Tamara S Flys; Anthony Mwatha; Laura A Guay; Clemensia Nakabiito; Deborah Donnell; Philippa Musoke; Francis Mmiro; J Brooks Jackson; Susan H Eshleman Journal: AIDS Date: 2007-10-01 Impact factor: 4.177
Authors: D Havlir; S H Cheeseman; M McLaughlin; R Murphy; A Erice; S A Spector; T C Greenough; J L Sullivan; D Hall; M Myers Journal: J Infect Dis Date: 1995-03 Impact factor: 5.226
Authors: A M Stek; B M Best; W Luo; E Capparelli; S Burchett; C Hu; H Li; J S Read; A Jennings; E Barr; E Smith; S S Rossi; M Mirochnick Journal: HIV Med Date: 2011-11-30 Impact factor: 3.180
Authors: Anna H Tran; Brookie M Best; Alice Stek; Jiajia Wang; Edmund V Capparelli; Sandra K Burchett; Regis Kreitchmann; Kittipong Rungruengthanakit; Kathleen George; Tim R Cressey; Nahida Chakhtoura; Elizabeth Smith; David E Shapiro; Mark Mirochnick Journal: J Acquir Immune Defic Syndr Date: 2016-07-01 Impact factor: 3.731